Furthermore, in vitro and in vivo demonstrations revealed that treatment with buparlisib (BKM120), a pan-PI3K class 1 inhibitor with excellent BBB penetrance, reduced the macrophage or microglia-induced invasion and glial-assisted infiltration of breast cancer cells into the brain parenchyma [159]. This evidence concerns the gene PIK3CA and breast cancer.